Comparison/NN
of/IN
the/DT
MGISEQ-2000/NN
and/CC
Illumina/NN
HiSeq/NN
4000/CD
sequencing/NN
platforms/NNS
for/IN
RNA/NN
sequencing/NN
./.
====================
Currently/RB
,/,
Illumina/NN
sequencers/NNS
are/VBP
the/DT
globally/RB
leading/VBG
sequencing/NN
platform/NN
in/IN
the/DT
next-generation/NN
sequencing/NN
market/NN
./.
====================
Recently/RB
,/,
MGI/NN
Tech/JJ
launched/VBN
a/DT
series/NN
of/IN
new/JJ
sequencers/NNS
,/,
including/VBG
the/DT
MGISEQ-2000/NN
,/,
which/WDT
promise/VBP
to/TO
deliver/VB
high-quality/JJ
sequencing/NN
data/NNS
faster/JJR
and/CC
at/IN
lower/JJR
prices/NNS
than/IN
Illumina/NN
’/CD
s/NNS
sequencers/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
compared/VBD
the/DT
performance/NN
of/IN
two/CD
major/JJ
sequencers/NNS
(/(
MGISEQ-2000/CD
and/CC
HiSeq/JJ
4000/CD
)/)
to/TO
test/VB
whether/IN
the/DT
MGISEQ-2000/NN
sequencer/NN
delivers/VBZ
high-quality/JJ
sequence/NN
data/NNS
as/IN
suggested/VBD
./.
====================
We/PRP
performed/VBD
RNA/NN
sequencing/NN
of/IN
four/CD
human/JJ
colon/NN
cancer/NN
samples/NNS
with/IN
the/DT
two/CD
platforms/NNS
,/,
and/CC
compared/VBN
the/DT
sequencing/NN
quality/NN
and/CC
expression/NN
values/NNS
./.
====================
The/DT
data/NNS
produced/VBD
from/IN
the/DT
MGISEQ-2000/NN
and/CC
HiSeq/JJ
4000/CD
showed/VBD
high/JJ
concordance/NN
,/,
with/IN
Pearson/NN
correlation/NN
coefficients/NNS
ranging/VBG
from/IN
0.98/CD
to/TO
0.99/CD
./.
====================
Various/JJ
quality/NN
control/NN
(/(
QC/NN
)/)
analyses/NNS
showed/VBD
that/IN
the/DT
MGISEQ-2000/NN
data/NNS
fulfilled/VBD
the/DT
required/VBN
QC/NN
measures/NNS
./.
====================
Our/PRP$
study/NN
suggests/VBZ
that/IN
the/DT
performance/NN
of/IN
the/DT
MGISEQ-2000/NN
is/VBZ
comparable/JJ
to/TO
that/DT
of/IN
the/DT
HiSeq/JJ
4000/CD
and/CC
that/IN
the/DT
MGISEQ-2000/NN
can/MD
be/VB
a/DT
useful/JJ
platform/NN
for/IN
sequencing/NN
./.
====================
Next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technology/NN
has/VBZ
had/VBD
a/DT
major/JJ
impact/NN
on/IN
the/DT
field/NN
of/IN
genomics/NNS
since/IN
its/PRP$
first/JJ
release/NN
in/IN
2005/CD
[/(
1/CD
]/)
./.
====================
Since/IN
then/RB
,/,
many/JJ
different/JJ
NGS/NN
platforms/NNS
have/VBP
been/VBN
developed/VBN
,/,
adopting/VBG
different/JJ
strategies/NNS
and/CC
chemical/JJ
techniques/NNS
[/(
1/CD
]/)
./.
====================
However/RB
,/,
NGS/NN
machines/NNS
based/VBN
on/IN
Illumina/NN
’/CD
s/NNS
sequencing/NN
by/IN
synthesis/NN
method/NN
have/VBP
dominated/VBN
the/DT
sequencing/NN
market/NN
owing/VBG
to/TO
their/PRP$
high/JJ
accuracy/NN
and/CC
high/JJ
throughput/NN
./.
====================
The/DT
NovaSeq/JJ
6000/CD
,/,
the/DT
latest/JJ
instrument/JJ
of/IN
Illumina/NN
’/CD
s/NNS
series/NN
,/,
now/RB
generates/VBZ
6/CD
TB/NN
of/IN
sequence/NN
data/NNS
in/IN
a/DT
single/JJ
run/JJ
with/IN
a/DT
running/JJ
cost/JJ
of/IN
12-18/CD
USD/GB/NN
./.
====================
Recently/RB
,/,
MGI/NNP
Tech/JJ
,/,
a/DT
subsidiary/JJ
of/IN
the/DT
Beijing/JJ
Genomics/NNS
Institute/RB
(/(
BGI/NNP
)/)
Group/NN
,/,
launched/VBN
a/DT
series/NN
of/IN
new/JJ
NGS/NN
machines/NNS
(/(
the/DT
BGI-200/CD
,/,
BGI-500/CD
,/,
MGISEQ-2000/CD
,/,
and/CC
MGISEQ-T7/NN
)/)
based/VBN
on/IN
DNA/NN
nanoball/NN
technology/NN
;/:
these/DT
devices/NNS
promise/RB
to/TO
deliver/RB
high-quality/JJ
sequencing/NN
data/NNS
faster/JJR
at/IN
lower/JJR
prices/VBZ
./.
====================
For/IN
example/NN
,/,
the/DT
MGISEQ-2000/NN
currently/RB
generates/VBZ
1.44/CD
TB/NN
of/IN
sequence/NN
data/NNS
in/IN
a/DT
single/JJ
run/JJ
with/IN
a/DT
running/JJ
cost/JJS
of/IN
10/CD
USD/GB/NN
./.
====================
Several/JJ
recent/JJ
studies/NNS
have/VBP
compared/VBN
the/DT
performance/NN
of/IN
BGI/NN
sequencers/NNS
with/IN
Illumina/NN
’/NNP
s/NNS
sequencers/NNS
and/CC
showed/VBD
that/IN
the/DT
BGI/NN
sequencers/NNS
produced/VBN
high-quality/JJ
sequence/NN
data/NNS
at/IN
lower/JJR
or/CC
similar/JJ
prices/NNS
in/IN
studies/NNS
of/IN
whole-exome/DT
[/(
2,3/CD
]/)
,/,
whole-genome/DT
[/(
4/CD
]/)
[/(
1/CD
]/)
,/,
transcriptome/DT
[/(
5,6/CD
]/)
,/,
single-cell/JJ
transcriptome/DT
[/(
2,78/CD
]/)
,/,
metagenome/JJ
[/(
9/CD
]/)
,/,
and/CC
small/JJ
RNA/NN
sequencing/NN
[/(
10/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
compared/VBD
the/DT
performance/NN
of/IN
MGISEQ-2000/CD
with/IN
that/DT
of/IN
Illumina/NN
’/CD
s/NNS
HiSeq/NN
4000/CD
by/IN
sequencing/VBG
the/DT
same/JJ
RNAs/NNS
from/IN
four/CD
human/JJ
colorectal/JJ
cancer/NN
patients/NNS
’/CD
tissue/NN
samples/NNS
./.
====================
We/PRP
found/VBD
that/IN
the/DT
MGISEQ-2000/NN
produced/VBN
high-quality/JJ
sequence/NN
data/NNS
comparable/JJ
to/TO
the/DT
data/NNS
obtained/VBN
by/IN
the/DT
HiSeq/JJ
4000/CD
,/,
at/IN
half/NN
the/DT
price/JJ
./.
====================
We/PRP
suggest/VBP
that/IN
the/DT
MGISEQ-2000/NN
is/VBZ
a/DT
promising/JJ
sequencing/NN
platform/NN
for/IN
whole-transcriptomics/NNS
studies/NNS
with/IN
high/JJ
performance/NN
and/CC
low/JJ
cost/NN
./.
====================
RNA/NN
extraction/NN
,/,
library/NN
construction/NN
,/,
and/CC
sequencing/NN
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
four/CD
human/JJ
colon/NN
tissue/NN
samples/NNS
using/VBG
an/DT
RNeasy/NN
Blood/NN
and/CC
Tissue/NN
kit/NN
(/(
Qiagen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
To/TO
construct/VB
the/DT
sequencing/NN
library/NN
for/IN
HiSeq/JJ
4000/CD
,/,
we/PRP
followed/VBD
the/DT
TruSeq/NN
Stranded/JJ
mRNA/NN
Sample/NN
Preparation/NN
Guide/NN
,/,
Part/NN
#/CD
15031047/CD
Rev/NN
./.
====================
E./FW
Approximately/RB
2/CD
μg/JJ
of/IN
total/JJ
RNA/NN
was/VBD
used/VBN
for/IN
library/NN
construction/NN
with/IN
the/DT
Illumina/NN
TruSeq/NN
Stranded/JJ
mRNA/NN
Library/JJ
Prep/JJ
Kit/NN
(/(
San/NN
Diego/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
Next/RB
,/,
paired-end/NN
sequencing/NN
was/VBD
performed/VBN
using/VBG
the/DT
Illumina/NN
HiSeq4000/CD
sequencing/NN
instrument/JJ
,/,
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
,/,
yielding/VBG
101-bp/JJ
paired-end/NN
reads/VBZ
./.
====================
To/TO
construct/VB
the/DT
library/NN
for/IN
the/DT
MGISEQ-2000/NN
,/,
approximately/RB
1/CD
μg/NN
of/IN
total/JJ
RNA/NN
was/VBD
used/VBN
for/IN
library/NN
construction/NN
using/VBG
the/DT
MGIEasy/NN
RNA/NN
Directional/JJ
Library/JJ
Prep/JJ
Kit/NN
(/(
MGI/NN
)/)
./.
====================
Next/RB
,/,
paired-end/NN
sequencing/NN
was/VBD
performed/VBN
using/VBG
the/DT
MGISEQ-2000/NN
sequencing/NN
instrument/JJ
,/,
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
,/,
yielding/VBG
100-bp/JJ
paired-end/NN
reads/VBZ
./.
====================
The/DT
RNA-seq/NN
data/NNS
of/IN
HiSeq/JJ
4000/CD
were/VBD
generated/VBN
in/IN
2013/CD
,/,
while/IN
the/DT
MGISEQ-2000/NN
data/NNS
were/VBD
generated/VBN
in/IN
2019/CD
./.
====================
Thus/RB
,/,
although/IN
we/PRP
used/VBD
RNA/NN
from/IN
the/DT
same/JJ
samples/NNS
,/,
the/DT
sequencing/NN
was/VBD
not/RB
performed/VBN
at/IN
the/DT
same/JJ
time/NN
./.
====================
Sequencing/NN
quality/NN
check/NN
,/,
mapping/VBG
,/,
and/CC
data/NNS
analysis/NN
====================
We/PRP
used/VBD
FastQC/NN
v0.11.5/CD
to/TO
check/VB
the/DT
quality/NN
of/IN
the/DT
sequencing/NN
results/NNS
./.
====================
The/DT
simple/JJ
Python/NN
script/NN
q30/NN
(/(
https/NNS
:/:
//github.com/dayedepps/q30/CD
)/)
was/VBD
used/VBN
to/TO
calculate/JJ
the/DT
exact/JJ
percentages/NNS
of/IN
Q20/Q30/NN
./.
====================
We/PRP
used/VBD
STAR_2.5.4b/JJ
,/,
an/DT
ultrafast/JJ
universal/JJ
RNA-seq/NN
aligner/NN
,/,
to/TO
align/VB
the/DT
RNA-seq/NN
data/NNS
onto/IN
the/DT
hg19/NN
reference/VBP
genome/NN
[/(
11/CD
]/)
./.
====================
We/PRP
ran/VBP
the/DT
mapping/NN
job/NN
with/IN
the/DT
quantMode/NN
set/NN
as/IN
the/DT
GeneCounts/NNS
option/NN
./.
====================
Using/VBG
the/DT
R/NN
statistical/JJ
language/NN
,/,
we/PRP
normalized/VBD
the/DT
read/JJ
count/NN
data/NNS
and/CC
converted/VBD
its/PRP$
scale/NN
into/IN
the/DT
base/NN
2/CD
logarithm/NN
of/IN
counts/NNS
per/IN
million/NN
(/(
cpm/NN
)/)
./.
====================
A/DT
scatter/NN
plot/NN
was/VBD
drawn/VBN
using/VBG
ggscatter/JJ
,/,
one/CD
of/IN
the/DT
functions/NNS
of/IN
the/DT
R/NN
package/NN
ggpubr/NN
./.
====================
Correlation/NN
graphs/NNS
were/VBD
drawn/VBN
using/VBG
Microsoft/JJ
Excel/JJ
2013/CD
./.
====================
The/DT
data/NNS
used/VBN
in/IN
drawing/VBG
scatter/NN
plot/NN
and/CC
correlation/NN
graphs/NNS
were/VBD
normalized/VBN
and/CC
converted/VBD
into/IN
the/DT
base/NN
2/CD
logarithm/NN
of/IN
cpm/NN
,/,
as/IN
mentioned/VBN
above/JJ
./.
====================
To/TO
obtain/VB
Venn/NNP
diagrams/NNS
of/IN
the/DT
upregulated/VBN
differentially/RB
expressed/VBN
genes/NNS
(/(
DEGs/NNS
)/)
and/CC
the/DT
downregulated/JJ
DEGs/NNS
,/,
we/PRP
used/VBD
jvenn/IN
,/,
an/DT
interactive/JJ
Venn/NNP
diagram/NN
viewer/JJR
(/(
http/NN
:/:
//jvenn.toulouse.inra.fr/app/index.html/NN
)/)
[/(
12/CD
]/)
./.
====================
Comparison/NN
of/IN
sequencing/NN
and/CC
mapping/NN
data/NNS
quality/NN
====================
We/PRP
sequenced/VBD
four/CD
human/JJ
colon/NN
tumor/NN
tissue/NN
samples/NNS
with/IN
Illumina/NN
’/CD
s/NNS
HiSeq/NN
4000/CD
and/CC
the/DT
MGISEQ-2000/NN
,/,
and/CC
checked/VBD
the/DT
quality/NN
of/IN
the/DT
sequences/NNS
by/IN
running/VBG
the/DT
FastQC/NN
program/NN
./.
====================
Overall/RB
,/,
the/DT
sequence/NN
quality/NN
of/IN
the/DT
two/CD
platforms/NNS
was/VBD
similar/JJ
./.
====================
In/IN
terms/NNS
of/IN
the/DT
Phred/JJ
score/RB
,/,
the/DT
MGISEQ-2000/NN
showed/VBD
a/DT
higher/JJR
percentage/NN
for/IN
over-Q20/NN
bases/NNS
,/,
but/CC
a/DT
lower/JJR
percentage/NN
for/IN
over-Q30/NN
bases/NNS
than/IN
the/DT
Illumina/NN
HiSeq/JJ
4000/CD
(/(
Table/JJ
1/CD
)/)
./.
====================
For/IN
over-Q20/NN
bases/NNS
,/,
the/DT
HiSeq/JJ
4000/CD
showed/VBD
an/DT
average/NN
of/IN
97.84/CD
%/NN
and/CC
the/DT
MGISEQ-2000/NN
showed/VBD
an/DT
average/NN
of/IN
98.20/CD
%/NN
./.
====================
For/IN
over-Q30/NN
bases/NNS
,/,
the/DT
HiSeq/JJ
4000/CD
showed/VBD
an/DT
average/NN
of/IN
94.63/CD
%/NN
and/CC
the/DT
MGISEQ-2000/NN
showed/VBD
an/DT
average/NN
of/IN
92.60/CD
%/NN
./.
====================
For/IN
uniquely/RB
mapped/VBD
reads/VBZ
,/,
the/DT
MGISEQ-2000/NN
produced/VBN
better/RBR
mapping/NN
results/VBZ
than/IN
the/DT
HiSeq/JJ
4000/CD
in/IN
all/DT
four/CD
samples/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
On/IN
average/NN
,/,
the/DT
sequencing/NN
reads/VBZ
from/IN
the/DT
MGISEQ-2000/NN
mapped/VBD
2.3/CD
%/NN
more/RBR
data/NNS
than/IN
the/DT
HiSeq/JJ
4000/CD
./.
====================
Concordance/NN
between/IN
the/DT
MGISEQ-2000/CD
and/CC
HiSeq/NN
4000/CD
====================
We/PRP
checked/VBD
the/DT
concordance/NN
of/IN
the/DT
RNA-seq/NN
data/NNS
produced/VBD
by/IN
the/DT
two/CD
platforms/NNS
using/VBG
two/CD
methods/NNS
:/:
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
of/IN
the/DT
eight/CD
samples/NNS
,/,
and/CC
pairwise/JJ
correlation/NN
analysis/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
When/WRB
we/PRP
performed/VBD
PCA/NN
of/IN
the/DT
eight/CD
samples/NNS
,/,
we/PRP
found/VBD
that/IN
the/DT
four/CD
pairs/NNS
of/IN
samples/NNS
were/VBD
located/JJ
close/RB
to/TO
each/DT
other/JJ
,/,
showing/VBG
that/IN
no/DT
significant/JJ
biases/NNS
existed/VBD
between/IN
the/DT
two/CD
sequencing/NN
platforms/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Then/RB
,/,
we/PRP
calculated/VBD
the/DT
Pearson/NN
correlation/NN
coefficient/JJ
of/IN
the/DT
four/CD
pairs/NNS
and/CC
found/VBD
that/IN
all/DT
four/CD
pairs/NNS
of/IN
samples/NNS
showed/VBD
high/JJ
correlation/NN
coefficients/NNS
,/,
ranging/VBG
from/IN
0.98/CD
to/TO
0.99/CD
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Thus/RB
,/,
we/PRP
found/VBD
that/IN
the/DT
MGISEQ-2000/NN
and/CC
HiSeq/JJ
4000/CD
produced/VBN
highly/RB
reproducible/JJ
data/NNS
from/IN
the/DT
same/JJ
samples/NNS
without/IN
significant/JJ
platform-specific/JJ
biases/NNS
./.
====================
DEGs/NNS
between/IN
the/DT
MGISEQ-2000/CD
and/CC
HiSeq/NN
4000/CD
====================
We/PRP
observed/VBD
a/DT
small/JJ
number/NN
of/IN
DEGs/NNS
(/(
fold/JJ
change/NN
over/IN
two/CD
)/)
between/IN
the/DT
MGISEQ-2000/NN
and/CC
HiSeq/JJ
4000/CD
platforms/NNS
(/(
Supplementary/JJ
Tables/NNS
1–4/CD
)/)
,/,
but/CC
most/JJS
of/IN
them/PRP
were/VBD
random/JJ
DEGs/NNS
without/IN
systematic/JJ
bias/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Among/IN
the/DT
four/CD
pairs/NNS
of/IN
samples/NNS
(/(
P1/NN
,/,
P2/NN
,/,
P3/NN
,/,
and/CC
P4/NN
)/)
,/,
there/EX
were/VBD
409/CD
,/,
838/CD
,/,
477/CD
,/,
and/CC
1152/CD
downregulated/VBD
DEGs/NNS
,/,
and/CC
171/CD
,/,
390/CD
,/,
167/CD
,/,
and/CC
414/CD
upregulated/VBN
DEGs/NNS
,/,
respectively/RB
./.
====================
We/PRP
further/RB
searched/VBD
for/IN
overlapping/VBG
genes/NNS
and/CC
found/VBD
that/IN
there/EX
were/VBD
132/CD
downregulated/VBD
DEGs/NNS
and/CC
94/CD
upregulated/VBN
DEGs/NNS
that/DT
were/VBD
common/JJ
among/IN
the/DT
four/CD
pairs/NNS
of/IN
samples/NNS
(/(
P1/NN
,/,
P2/NN
,/,
P3/NN
,/,
and/CC
P4/NN
)/)
./.
====================
In/IN
detail/NN
,/,
among/IN
the/DT
downregulated/JJ
DEGs/NNS
in/IN
P2/NN
,/,
664/CD
of/IN
839/CD
genes/NNS
(/(
approximately/RB
80/CD
%/NN
)/)
(/(
Fig/NN
./.
====================
3/CD
,/,
Supplementary/JJ
Table/JJ
5/CD
)/)
were/VBD
also/RB
downregulated/VBD
in/IN
P4/NN
./.
====================
Considering/VBG
that/WDT
P4/NN
had/VBD
many/JJ
downregulated/JJ
DEGs/NNS
compared/VBN
to/TO
other/JJ
samples/NNS
,/,
it/PRP
still/RB
showed/VBD
quite/RB
a/DT
high/JJ
percentage/NN
of/IN
intersection/NN
with/IN
P2/NN
(/(
about/RB
58/CD
%/NN
)/)
(/(
Fig/NN
./.
====================
3/CD
,/,
Supplementary/JJ
Table/JJ
5/CD
)/)
./.
====================
For/IN
upregulated/VBN
DEGs/NNS
,/,
we/PRP
also/RB
noticed/VBN
that/DT
P2/NN
and/CC
P4/NN
shared/VBN
a/DT
substantial/JJ
proportion/NN
of/IN
upregulated/VBN
DEGs/NNS
(/(
over/IN
70/CD
%/NN
)/)
(/(
Fig/NN
./.
====================
3/CD
,/,
Supplementary/JJ
Table/JJ
6/CD
)/)
,/,
even/RB
though/IN
they/PRP
had/VBD
more/RBR
upregulated/VBN
DEGs/NNS
than/IN
the/DT
other/JJ
samples/NNS
(/(
P1/NN
,/,
P3/NN
)/)
./.
====================
As/IN
we/PRP
conducted/VBD
a/DT
gene/NN
ontology/RB
analysis/NN
,/,
we/PRP
found/VBD
that/IN
ribosomal/JJ
protein-coding/VBG
genes/NNS
showed/VBD
some/DT
tendency/NN
to/TO
be/VB
present/JJ
among/IN
the/DT
downregulated/JJ
DEGs/NNS
(/(
Supplementary/JJ
Table/JJ
7/CD
)/)
,/,
while/IN
genes/NNS
related/JJ
to/TO
transcription/NN
showed/VBD
a/DT
slight/JJ
tendency/NN
to/TO
be/VB
present/JJ
among/IN
the/DT
upregulated/VBN
DEGs/NNS
(/(
Supplementary/JJ
Table/JJ
8/CD
)/)
./.
====================
However/RB
,/,
as/IN
mentioned/VBN
in/IN
the/DT
Methods/NNS
section/NN
,/,
we/PRP
did/VBD
not/RB
generate/VB
the/DT
two/CD
sets/NNS
of/IN
RNA-seq/JJ
data/NNS
at/IN
the/DT
same/JJ
time/NN
,/,
leading/VBG
to/TO
the/DT
concern/NN
that/DT
some/DT
degradation/NN
of/IN
the/DT
RNA/NN
samples/NNS
may/MD
have/VB
taken/VBN
place/NN
over/IN
the/DT
6-year/JJ
interval/JJ
./.
====================
Another/DT
limitation/NN
is/VBZ
that/DT
we/PRP
sequenced/VBD
each/DT
sample/NN
for/IN
each/DT
platform/NN
once/RB
without/IN
duplicates/NNS
,/,
which/WDT
may/MD
have/VB
increased/VBN
the/DT
likelihood/NN
of/IN
errors/NNS
./.
====================
While/IN
sequencing/NN
costs/NNS
have/VBP
declined/VBN
significantly/RB
over/IN
the/DT
years/NNS
,/,
the/DT
ever-increasing/VBG
sample/NN
size/NN
and/CC
scale/NN
of/IN
omics/NNS
projects/NNS
necessitate/JJ
the/DT
use/NN
of/IN
sequencing/NN
technology/NN
with/IN
lower/JJR
costs/NNS
./.
====================
In/IN
this/DT
regard/NN
,/,
sequencing/NN
instruments/NNS
such/JJ
as/IN
the/DT
BGI-500/CD
,/,
MGISEQ-2000/CD
,/,
and/CC
MGISEQ-T7/NN
are/VBP
attractive/JJ
alternatives/VBZ
to/TO
Illumina/NN
’/CD
s/NNS
HiSeq/NN
and/CC
NovaSeq/JJ
series/NNS
,/,
as/IN
they/PRP
enable/VBP
researchers/NNS
to/TO
generate/VB
the/DT
same/JJ
amount/NN
of/IN
data/NNS
at/IN
lower/JJR
costs/NNS
./.
====================
Several/JJ
recent/JJ
papers/NNS
have/VBP
compared/VBN
the/DT
performance/NN
of/IN
the/DT
BGI-500/CD
with/IN
that/DT
of/IN
Illumina/NN
’/NNP
s/NNS
HiSeq/NN
machines/NNS
and/CC
showed/VBD
that/IN
both/CC
machines/NNS
produced/VBN
high-quality/JJ
data/NNS
in/IN
diverse/JJ
applications/NNS
such/JJ
as/IN
whole-exome/DT
[/(
3/CD
]/)
,/,
whole-genome/DT
[/(
13-15/CD
]/)
,/,
small/JJ
RNA/NN
[/(
10/CD
]/)
,/,
and/CC
metagenome/JJ
sequencing/NN
[/(
9/CD
]/)
,/,
as/IN
well/RB
as/IN
plant-tissue/NN
transcriptomics/VBZ
[/(
5/CD
]/)
and/CC
single-cell/JJ
transcriptomics/VBZ
[/(
7,8/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
also/RB
found/VBD
that/IN
the/DT
MGISEQ-2000/NN
and/CC
HiSeq/JJ
4000/CD
produced/VBN
highly/RB
concordant/JJ
gene/NN
expression/NN
data/NNS
from/IN
the/DT
four/CD
colorectal/JJ
tumor/NN
tissue/NN
samples/NNS
./.
====================
While/IN
the/DT
two/CD
platforms/NNS
exhibit/VBP
similar/JJ
base/NN
sequencing/NN
quality/NN
,/,
we/PRP
found/VBD
that/IN
the/DT
MGISEQ-2000/NN
produced/VBN
sequencing/NN
data/NNS
with/IN
higher/JJR
mapping/NN
quality/NN
than/IN
the/DT
HiSeq/JJ
4000/CD
in/IN
all/DT
samples/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
A/DT
recent/JJ
study/NN
also/RB
reported/VBD
that/IN
the/DT
MGISEQ-2000/NN
platform/NN
performed/VBN
consistently/RB
better/RBR
than/IN
the/DT
NextSeq/JJ
500/CD
platform/NN
in/IN
a/DT
single-cell/JJ
transcriptomics/NNS
study/NN
,/,
detecting/VBG
more/RBR
cells/NNS
,/,
genes/NNS
,/,
and/CC
unique/JJ
molecular/JJ
identifiers/NNS
[/(
8/CD
]/)
./.
====================
They/PRP
also/RB
reported/VBD
that/IN
the/DT
MGISEQ-2000/NN
produced/VBN
more/RBR
single-nucleotide/JJ
polymorphism/NN
calls/NNS
from/IN
sequence/NN
data/NNS
,/,
enabling/VBG
an/DT
additional/JJ
14/CD
%/NN
of/IN
cells/NNS
to/TO
be/VB
assigned/VBN
to/TO
the/DT
correct/JJ
donor/NN
from/IN
a/DT
multiplexed/JJ
library/NN
[/(
8/CD
]/)
./.
====================
Thus/RB
,/,
we/PRP
conclude/VBP
that/IN
the/DT
MGISEQ-2000/NN
is/VBZ
a/DT
robust/JJ
sequencing/NN
platform/NN
that/DT
produces/VBZ
high-quality/JJ
sequencing/NN
data/NNS
at/IN
lower/JJR
costs/NNS
and/CC
can/MD
be/VB
used/VBN
in/IN
many/JJ
NGS/NN
applications/NNS
./.
====================
High/JJ
concordance/NN
of/IN
RNA-seq/NN
data/NNS
produced/VBD
using/VBG
the/DT
Illumina/NN
and/CC
MGI/NN
platforms/NNS
as/IN
shown/VBN
by/IN
a/DT
principal/JJ
component/NN
analysis/NN
plot/NN
./.
====================
RNA/NN
from/IN
the/DT
four/CD
samples/NNS
was/VBD
sequenced/VBN
using/VBG
the/DT
HiSeq/JJ
4000/CD
(/(
blue/JJ
dots/NNS
)/)
and/CC
MGISEQ-2000/CD
(/(
red/JJ
dots/NNS
)/)
sequencers/VBZ
./.
====================
Scatter/NN
plots/NNS
of/IN
gene/NN
expression/NN
values/NNS
of/IN
the/DT
four/CD
pairs/NNS
of/IN
samples/NNS
produced/VBN
using/VBG
the/DT
HiSeq/JJ
4000/CD
and/CC
MGISEQ-2000/CD
sequencers/NNS
./.
====================
Gene/NN
expression/NN
values/NNS
are/VBP
represented/VBN
as/IN
the/DT
base/NN
2/CD
logarithm/NN
of/IN
counts/NNS
per/FW
million/NN
(/(
cpm/NN
)/)
./.
====================
The/DT
Pearson/NN
correlation/NN
coefficients/NNS
of/IN
the/DT
four/CD
samples/NNS
were/VBD
between/IN
0.98/CD
and/CC
0.99/CD
./.
====================
Differentially/RB
expressed/VBN
genes/NNS
between/IN
the/DT
two/CD
platforms/NNS
./.
====================
Genes/NNS
with/IN
larger/JJR
than/IN
two-fold/RB
differences/NNS
were/VBD
selected/VBN
from/IN
the/DT
four/CD
pairs/NNS
of/IN
samples/NNS
./.
====================
As/IN
only/RB
one/CD
experiment/NN
was/VBD
performed/VBN
for/IN
each/DT
platform/NN
,/,
no/DT
statistical/JJ
test/NN
was/VBD
applied/VBN
./.
====================
The/DT
overlap/JJ
of/IN
the/DT
differentially/RB
expressed/VBN
genes/NNS
is/VBZ
shown/VBN
./.
====================
Summary/JJ
statistics/NNS
of/IN
sequencing/NN
quality/NN
====================
